2. Search Result
Search Result
Results for "

samrotecan

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Peptides

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171124
    Tilatamig samrotecan

    AZD9592

    		 Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis Cancer
    Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .
    Tilatamig samrotecan
  • HY-P3669
    Gly-Gly-Phe-Gly

    		ADC Linker Drug Intermediate Cancer
    Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689) .
    Gly-Gly-Phe-Gly
  • HY-171689
    Puxitatug samrotecan

    AZD 8205; P-Sam

    		 Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR +/HER2 - breast cancer .
    Puxitatug samrotecan
  • HY-P991699
    Lixarkitug

    AZD9829 antibody; INT-020

    		 ADC Antibody Interleukin Related Cancer
    Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lixarkitug
  • HY-P990059
    Puxitatug

    INT-016; AZD8205 Antibody

    		 ADC Antibody CD276/B7-H3 Cancer
    Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
    Puxitatug
  • HY-163487
    Puxitatug samrotecan drug-linker

    AZD8205 drug-linker

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is a drug-linker conjugate for ADC, which comprises a topoisomerase I inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesis antibody-drug conjugate (ADC), Puxitatug samrotecan (HY-171689) .
    Puxitatug samrotecan drug-linker
  • HY-P990947
    Tilatamig

    AZD9592 Antibody

    		 ADC Antibody EGFR Cancer
    Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .
    Tilatamig
  • HY-181428
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC) .
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: